Skip to main content

Research Repository

Advanced Search

Targeting splicing in prostate cancer

Antonopoulou, Effrosyni; Ladomery, Michael


Effrosyni Antonopoulou


© 2018 by the authors. Licensee MDPI, Basel, Switzerland. Over 95% of human genes are alternatively spliced, expressing splice isoforms that often exhibit antagonistic functions. We describe genes whose alternative splicing has been linked to prostate cancer; namely VEGFA, KLF6, BCL2L2, ERG, and AR. We discuss opportunities to develop novel therapies that target specific splice isoforms, or that target the machinery of splicing. Therapeutic approaches include the development of small molecule inhibitors of splice factor kinases, splice isoform specific siRNAs, and splice switching oligonucleotides.


Antonopoulou, E., & Ladomery, M. (2018). Targeting splicing in prostate cancer. International Journal of Molecular Sciences, 19(5), 1287.

Journal Article Type Review
Acceptance Date Apr 25, 2018
Online Publication Date Apr 25, 2018
Publication Date May 1, 2018
Journal International Journal of Molecular Sciences
Print ISSN 1661-6596
Electronic ISSN 1422-0067
Publisher MDPI
Peer Reviewed Peer Reviewed
Volume 19
Issue 5
Pages 1287
Keywords alternative splicing, prostate cancer, VEGFA, KLF6, BCL2L2, ERG, AR, splice switching oligonucleotides, RNA interference, splice factors, splice factor kinases
Public URL
Publisher URL


You might also like

Downloadable Citations